You are here

  • Home
  • Archive
  • Volume 73, Issue 9
  • Response to: ‘Is there a direct relationship between serum level of methotrexate and clinical efficacy and tolerability?’ by Fleishman and Yazici

Article Text

Article menu
Download PDFPDF
Electronic pages
Correspondence response
Response to: ‘Is there a direct relationship between serum level of methotrexate and clinical efficacy and tolerability?’ by Fleishman and Yazici
  1. Michael H Schiff1,
  2. Jonathan S Jaffe2,
  3. Bruce Freundlich3
  1. 1Department of Rheumatology, University of Colorado, Englewood, Colorado, USA
  2. 2Clinical Development, Antares Pharma Inc, Ewing, New Jersey, USA
  3. 3Medical Department, Antares Pharma Inc, Ewing, New Jersey, USA
  1. Correspondence to Dr Michael H Schiff, Department of Rheumatology, University of Colorado, 5400 South Monaco, Englewood, Colorado CO 80111, USA; michael.schiff{at}me.com

https://doi.org/10.1136/annrheumdis-2014-205938

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Drs Fleishman and Yazici pose several worthwhile questions.1 It is important to appreciate that this was not a clinical trial, but rather a classic pharmacokinetic study. Unlike previous studies, ours compared commonly used doses of two different formulations of methotrexate (MTX), subcutaneous (SC) and oral. The key concept demonstrated is that the absorption of oral MTX is both variable and saturable. Because there is extensive overlap in the …

    View Full Text

    Footnotes

    • Competing interests None.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles